GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Enterprise Value

Vigil Neuroscience (Vigil Neuroscience) Enterprise Value : $31.50 Mil (As of May. 13, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vigil Neuroscience's Enterprise Value is $31.50 Mil. Vigil Neuroscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-89.51 Mil. Therefore, Vigil Neuroscience's EV-to-EBIT ratio for today is -0.35.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Vigil Neuroscience's Enterprise Value is $31.50 Mil. Vigil Neuroscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-89.06 Mil. Therefore, Vigil Neuroscience's EV-to-EBITDA ratio for today is -0.35.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Vigil Neuroscience's Enterprise Value is $31.50 Mil. Vigil Neuroscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Vigil Neuroscience's EV-to-Revenue ratio for today is .


Vigil Neuroscience Enterprise Value Historical Data

The historical data trend for Vigil Neuroscience's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vigil Neuroscience Enterprise Value Chart

Vigil Neuroscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 258.82 17.20

Vigil Neuroscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 199.38 201.15 73.77 17.20 40.15

Competitive Comparison of Vigil Neuroscience's Enterprise Value

For the Biotechnology subindustry, Vigil Neuroscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vigil Neuroscience's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vigil Neuroscience's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Vigil Neuroscience's Enterprise Value falls into.



Vigil Neuroscience Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Vigil Neuroscience's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Vigil Neuroscience's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vigil Neuroscience  (NAS:VIGL) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Vigil Neuroscience's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=31.503/-89.506
=-0.35

Vigil Neuroscience's current Enterprise Value is $31.50 Mil.
Vigil Neuroscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.51 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Vigil Neuroscience's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=31.503/-89.059
=-0.35

Vigil Neuroscience's current Enterprise Value is $31.50 Mil.
Vigil Neuroscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.06 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Vigil Neuroscience's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=31.503/0
=

Vigil Neuroscience's current Enterprise Value is $31.50 Mil.
Vigil Neuroscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vigil Neuroscience Enterprise Value Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vigil Neuroscience (Vigil Neuroscience) Business Description

Traded in Other Exchanges
N/A
Address
100 Forge Road, Suite 700, Watertown, MA, USA, 02472
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
Executives
Ivana Magovcevic-liebisch director, officer: President and CEO 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Christopher Silber officer: Chief Medical Officer C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Budd Haeberlein Samantha L. director VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F. officer: Chief Science Officer VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos officer: Chief Medical Officer C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry officer: SVP, Head of Early Development VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski officer: Chief Financial Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni officer: General Counsel VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Vida Ventures Gp Iii, L.l.c. 10 percent owner 455 MARKET STREET, SUITE 1420, SAN FRANCISCO CA 94105
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451

Vigil Neuroscience (Vigil Neuroscience) Headlines

From GuruFocus

Vigil Neuroscience to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-07-2022

Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023